Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation.
Publication
, Journal Article
Lyons, MD; Lentz, AC; Coward, RM
Published in: Am J Mens Health
May 2017
Duke Scholars
Published In
Am J Mens Health
DOI
EISSN
1557-9891
Publication Date
May 2017
Volume
11
Issue
3
Start / End Page
618 / 619
Location
United States
Related Subject Headings
- Treatment Outcome
- Sexual Dysfunction, Physiological
- Public Health
- Off-Label Use
- Male
- Lisdexamfetamine Dimesylate
- Humans
- Ejaculation
- Central Nervous System Stimulants
- 4405 Gender studies
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyons, M. D., Lentz, A. C., & Coward, R. M. (2017). Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation. Am J Mens Health, 11(3), 618–619. https://doi.org/10.1177/1557988316658640
Lyons, Matthew D., Aaron C. Lentz, and Robert M. Coward. “Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation.” Am J Mens Health 11, no. 3 (May 2017): 618–19. https://doi.org/10.1177/1557988316658640.
Lyons MD, Lentz AC, Coward RM. Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation. Am J Mens Health. 2017 May;11(3):618–9.
Lyons, Matthew D., et al. “Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation.” Am J Mens Health, vol. 11, no. 3, May 2017, pp. 618–19. Pubmed, doi:10.1177/1557988316658640.
Lyons MD, Lentz AC, Coward RM. Lisdexamfetamine Dimesylate (Vyvanse) for the Treatment of Neurogenic Anejaculation. Am J Mens Health. 2017 May;11(3):618–619.
Published In
Am J Mens Health
DOI
EISSN
1557-9891
Publication Date
May 2017
Volume
11
Issue
3
Start / End Page
618 / 619
Location
United States
Related Subject Headings
- Treatment Outcome
- Sexual Dysfunction, Physiological
- Public Health
- Off-Label Use
- Male
- Lisdexamfetamine Dimesylate
- Humans
- Ejaculation
- Central Nervous System Stimulants
- 4405 Gender studies